Tiotropium Respimat^® in asthma is being investigated to investigate its efficacy and safety in people with asthma who are symptomatic despite at least ICS*/LABA**. Information includes a summary of the findings to date from the UniTinA-asthma clinical trial programme involving more than 4,000 patients in over 150 sites globally, that is addressing the unmet need of people with asthma who remain symtomatic despite today's therapies.